Pancreatin Market Size, Share & Forecast 2033

(MENAFN- Straits Research) Introduction

Pancreatin is a mixture of digestive enzymes, including amylase, lipase, and protease, derived from animal pancreas. It plays a vital role in breaking down carbohydrates, fats, and proteins, thereby supporting proper digestion and nutrient absorption. The pancreatin market is driven by increasing research into enzyme-based drug formulations and innovations in enzyme stabilization for improved efficacy.

Market Dynamics Rising prevalence of digestive disorders drives the global market

A major factor driving the global pancreatin market in 2025 is the increasing prevalence of digestive disorders. Growing incidences of gastrointestinal conditions such as enzyme insufficiency, malabsorption, and chronic pancreatitis are significantly boosting the demand for enzyme replacement therapies like pancreatin.

• In 2025, digestive disorders continue to be highly prevalent worldwide, with recent studies estimating around 2.28 billion people affected by one or more digestive conditions. Large-scale analyses also report irritable bowel syndrome (IBS) impacting approximately 14% of adults globally, with considerable regional differences.

This expanding patient population highlights the urgent need for effective enzyme supplements, propelling market growth as healthcare systems focus on improving digestive health management worldwide.

Expansion into functional foods and nutraceuticals creates tremendous opportunities

The global pancreatin market is set to witness substantial growth through its incorporation into functional foods and nutraceuticals. Rising consumer focus on digestive wellness and the growing trend toward preventive healthcare are fueling interest in enzyme-fortified products.

• For instance, Enzymedica offers pancreatin-based digestive supplements that support nutrient absorption and overall gut health, while NOW Foods provides enzyme formulations featuring pancreatin targeted at fitness enthusiasts and individuals with mild digestive issues.

With the functional food and nutraceutical sectors expanding globally, the integration of pancreatin into innovative dietary solutions creates a significant opportunity for manufacturers to broaden product portfolios and address shifting consumer demands.

Regional Analysis

North America is the dominant region in the global pancreatin market, driven by advanced healthcare infrastructure, high awareness, and rising incidences of digestive disorders. Strong pharmaceutical R&D and the presence of major industry players further strengthen growth in this region. For example, the increasing use of pancreatin in enzyme replacement therapies in the US highlights its expanding role in treating pancreatic insufficiency. Moreover, supportive regulations and high investments in biotechnology ensure North America maintains its leadership position, making it a critical hub for pancreatin development.

Key Highlights:

• The global pancreatin market size was valued at USD 121.35 million in 2024 and is estimated to grow from USD 128.46 million in 2025 to reach USD 207.93 million by 2033 , growing at a CAGR of 6.09% during the forecast period (2025–2033).
• By Source, the market is segmented into Porcine, Bovine, and Others. The porcine segment dominates the global market.
• By Form, the market is segmented into Powder, Granules, Tablets, and Capsules. The powder segment dominates the global market.
• By Application, the market is segmented into Pharmaceuticals, Food & Beverages, Animal Feed, and Others. The pharmaceutical segment dominates the global market.
• By Distribution Channel, the market is segmented into Online Stores, Pharmacies, Specialty Stores, and Others. The online store segment dominates the global market.
• North America is the highest shareholder in the global market.

Competitive Players

Nordmark Arzneimittel GmbH & Co. KG

Biozyme Laboratories

Amano Enzyme Inc.

Allergan plc

Abbott Laboratories

Nordic Pharma

Mylan N.V.

Digestive Care, Inc.

Advanced Enzyme Technologies Ltd.

Biovet JSC

Biosynth AG

Spectrum Chemical Manufacturing Corp.

Zytex Biotech Pvt. Ltd.

Enzyme Bioscience Pvt. Ltd.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

Sichuan Deebio Pharmaceutical Co., Ltd.

Jiangxi Tianxin Pharmaceutical Co., Ltd.

Chongqing Aoli Biopharmaceutical Co., Ltd.

Shanghai Yaxin Biotechnology Co., Ltd.

Shandong Zhongke Taidou Biological Technology Co., Ltd.

Recent Developments

• In March 2025 : Adalvo Limited introduced its Pancreatin Delayed-Release Capsules as a key innovation in enzyme replacement therapy. These capsules are specifically engineered to enhance enzyme stability and therapeutic efficacy by releasing their contents directly in the small intestine, bypassing the acidic environment of the stomach that typically degrades enzymes.

Segmentation

By Source

Porcine

Bovine

Others

By Form

Powder

Granules

Tablets

Capsules

By Application

Pharmaceuticals

Food & Beverages

Animal Feed

Others

By Distribution Channel

Online Stores

Pharmacies

Specialty Stores

Others

By Regions

North America

Europe

Asia-Pacific

Latin America

The Middle East and Africa

Want to see full report on
Pancreatin Market Full Report

MENAFN26092025004597010339ID1110115472